凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花集团:2013年第三季度报告

公告日期 2013-10-29
股票简称:梅花生物 股票代码:600873
    600873                 梅花生物科技集团股份有限公司 2013 年第三季度报告
         梅花生物科技集团股份有限公司
                    600873
             2013 年第三季度报告
    600873                        梅花生物科技集团股份有限公司 2013 年第三季度报告
                          目录一、重要提示 ............................................. 3二、公司主要财务数据和股东变化 ........................... 4三、重要事项 ............................................. 6四、附录 ................................................. 9
       600873                                    梅花生物科技集团股份有限公司 2013 年第三季度报告
    一、     重要提示1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    1.2     公司全体董事出席董事会审议季度报告。1.3
    公司负责人姓名                                      孟庆山
    主管会计工作负责人姓名                              李勇刚
    会计机构负责人(会计主管人员)姓名                  陶忠公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠保证季度报告中财务报表的真实、准确、完整。
    1.4     公司第三季度报告中的财务报表未经审计。
    600873                                         梅花生物科技集团股份有限公司 2013 年第三季度报告
    二、    公司主要财务数据和股东变化
    2.1    主要财务数据
                                                                             单位:元 币种:人民币
                                                                                     本报告期末比上
                                       本报告期末                上年度末
                                                                                     年度末增减(%)
    总资产                               18,468,766,746.00         17,098,314,827.01                 8.02
    归属于上市公司股东的净资产             7,898,245,692.53         5,481,286,521.83                44.09
                                     年初至报告期末        上年初至上年报告期末      比上年同期增减
                                       (1-9 月)              (1-9 月)                (%)
    经营活动产生的现金流量净额               713,455,223.11           887,878,143.70               -19.64
                                     年初至报告期末        上年初至上年报告期末      比上年同期增减
                                       (1-9 月)              (1-9 月)                (%)
    营业收入                               5,855,259,321.17         5,401,494,334.84                 8.40
    归属于上市公司股东的净利润               274,834,322.30           395,851,026.99               -30.57归属于上市公司股东的扣除非经
                                        164,153,852.59            288,424,800.50              -43.09常性损益的净利润
                                                                                    减少 3.55 个百分
    加权平均净资产收益率(%)                          3.86                     7.41
                                                                                                   点
    基本每股收益(元/股)                               0.09                     0.15                 -40
    稀释每股收益(元/股)                               0.09                     0.15                 -40扣除非经常性损益项目和金额:
                                                                            单位:元 币种:人民币
                                                本期金额                    年初至报告期末金额
              项目
                                              (7-9 月)                       (1-9 月)
    非流动资产处置损益                                       -16,468.82                        -59,468.40计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政
                                                     55,902,944.64                   124,788,580.41策规定、按照一定标准定额或定量持续享受的政府补助除外除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动
                                                      1,048,080.98                      2,259,836.69损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益除上述各项之外的其他营业外收入和
                                                     -1,524,462.12                     -1,487,607.17支出
    所得税影响额                                         -6,113,668.83                   -14,820,871.82
              合计                                   49,296,425.85                   110,680,469.71
    600873                                              梅花生物科技集团股份有限公司 2013 年第三季度报告
    2.2     截至报告期末的股东总数、前十名股东、前十名无限售条件股东的持股情况表
                                                                                               单位:股
                             股东总数                                                 63,669
                                          前十名股东持股情况
                                                                        持有有限售
                                            持股比
         股东名称              股东性质                    持股总数     条件股份数    质押或冻结的股份数量
                                            例(%)
                                                                            量
    孟庆山                     境内自然人         27.48       854,103,033   854,103,033   质押     705,070,000
    胡继军                     境内自然人         11.88       369,394,122                 质押     310,000,000香港鼎晖生物科技有限公
    司                         境外法人            8.87       275,625,120                 无新天域生化科技投资有限
    公司                       境外法人            8.24       256,106,616                 无建信基金公司-慧智投资8 号结构化集合资金信托
    计划                       其他                3.59       111,640,000   111,640,000   未知
    杨维永                     境内自然人          2.54        78,810,526    78,810,526   质押        74,900,000
    王爱军                     境内自然人          2.29        71,316,274    71,316,274   质押        71,316,274
    南京瑞森投资管理合伙企     境内非国有法
    业(有限合伙)             人                   2.1        65,170,000    65,170,000   未知
    昆明盈鑫叁壹投资中心(有   境内非国有法
    限合伙)                   人                  2.05        63,800,000    63,800,000   未知
    李宝骏                     境内自然人          1.87        58,020,019                 无
                                   前十名无限售条件流通股股东持股情况
                                             期末持有无限售条件流
            股东名称(全称)                       通股的数量                    股份种类及数量
    胡继军                                                    369,394,122      人民币普通股        369,394,122
    香港鼎晖生物科技有限公司                                  275,625,120      人民币普通股        275,625,120
    新天域生化科技投资有限公司                                256,106,616      人民币普通股        256,106,616
    李宝骏                                                     58,020,019      人民币普通股           58,020,019
    梁宇擘                                                     53,668,518      人民币普通股           53,668,518
    王加琪                                                     19,823,507      人民币普通股           19,823,507
    郭振群                                                     19,340,006      人民币普通股           19,340,006
    潘耀冬                                                     18,856,506      人民币普通股           18,856,506
    王友山                                                     18,131,256      人民币普通股           18,131,256山东省国际信托有限公司-联合证券价值联
    成三能 1 号证券投资集合资金信托计划                        14,933,844      人民币普通股           14,933,844
    上述股东关联关系或一致行动的说明        上述股东中,孟庆山、杨维永、王爱军为一致行动人。
    600873                                        梅花生物科技集团股份有限公司 2013 年第三季度报告三、 重要事项3.1 公司主要会计报表项目、财务指标重大变动的情况及原因√适用 □不适用
                                                                     单位:万元         币种:人民币资产负债表:
    项目                         本报告期末            上年度期末       增减额              增减幅度(%)
    应收票据                           11,158.71            35,316.02       -24,157.31             -68.4
    其他应收款                          7,341.07             3,100.82            4,240.25         136.75
    存货                              145,569.65            94,475.72        51,093.94             54.08
    固定资产                        1,076,345.77           577,329.59       499,016.18             86.44
    在建工程                          200,543.03           651,473.98      -450,930.95            -69.22
    工程物资                            3,081.97             9,902.26        -6,820.29            -68.88
    其他非流动资产                     67,207.61            42,323.68        24,883.93             58.79
    预收款项                           33,007.40            25,013.41            7,993.99          31.96
    资本公积                          224,048.59            18,752.84       205,295.75          1,094.74利润表:
    项目                         本报告期              上年同期         增减额              增减幅度(%)
    营业税金及附加                      2,680.91             1,348.56            1,332.35           98.8
    销售费用                           40,365.51            23,739.13        16,626.38             70.04
    财务费用                           13,834.96            23,714.75        -9,879.80            -41.66
    净利润                             27,483.43            39,585.10       -12,101.67            -30.57现金流量表:
    项目                         本报告期              上年同期         增减额              增减幅度(%)
    筹资活动产生的现金流量净额         97,152.99             7,126.63        90,026.35          1,263.24资产负债表:(1)应收票据比上年度期末下降 68.40%,主要原因是本报告期银行承兑汇票结算付款增加所致。(2)其他应收账款比上年度期末上升 136.75%,主要原因是本报告期公司支付了资产交割日前发生的、与五洲明珠有关的、延续到报告期内的诉讼款项所致。(3)存货比上年度期末上升 54.08%,主要原因是本报告期玉米及产成品库存增加所致。(4)固定资产比上年度期末上升 86.44%,主要原因是本报告期子公司新疆梅花氨基酸有限公司部分项目转固,增加固定资产所致。(5)在建工程比上年度期末下降 69.22%,主要原因是本报告期子公司新疆梅花氨基酸有限责任公司部分项目转固,减少在建工程所致。(6)工程物资比上年度期末下降 68.88%,主要原因是本报告期子公司新疆梅花氨基酸有限责任公司工程领用减少所致。(7)其他非流动资产比上年度期末上升 58.79%,主要原因是本报告期委托渤海国际信托有限公
    600873                                     梅花生物科技集团股份有限公司 2013 年第三季度报告司进行投资所致。(8)预收账款比上年度期末上升 31.96%,随销售收入增加预收款增加。(9)资本公积比上年度期末上升 1094.74%,主要原因是本报告期完成非公开发行股本溢价所致。利润表:(10)营业税金及附加比上年同期上升 98.80%,主要原因是本报告期应交流转税增加所致。(11)销售费用比上年同期上升 70.04%,主要原因是本报告期子公司新疆梅花氨基酸有限责任公司产能增加,销售量增加,导致运费增加所致。(12)财务费用比上年同期下降 41.66%,主要原因是本报告期非公开发行完成,银行借款减少,利息支出减少所致。(13)净利润比上年同期下降 30.57%,主要原因是本报告期由于受到禽流感及饲料氨基酸、味精市场竞争加剧的影响,公司主要产品味精、赖氨酸、苏氨酸等销售价格下滑所致。现金流量表:(14)筹资活动产生的现金流量净额比上年同期上升 1263.24%,主要原因是本报告期完成非公开发行股东投入资金增加所致。
    3.2    重要事项进展情况及其影响和解决方案的分析说明√适用 □不适用
      1.公司于 2013 年 3 月 22 日以非公开发行股票的方式向特定投资者发行了 39,999 万股人民币普通股(A 股)。(具体内容详见上海证券交易所公司 2013 年 4 月 3 日出具的公告《梅花生物科技集团股份有限公司非公开发行股票发行结果暨股本变动公告》)。
      公司本次发行完成后,公司股本总数已由 2,708,236,603 股变更为 3,108,226,603 股。公司已按照要求修订公司章程,并向外资主管部门提交了变更申请,获批后将及时向工商登记主管部门申请工商变更登记。
      2.公司目前尚有 15 起在资产交割日前发生的、与五洲明珠有关的、延续到报告期内的诉讼(诉讼具体内容详见公司 2013 年半年度报告中“第五节 重要事项”部分),其中陈素案、张治民案、张世龙案、周乐园及四川宏大建筑工程有限公司案已执行完毕,截止本报告出具日,合计执行金额 2883 万元 。根据前次重大资产重组时,公司前身五洲明珠与原控股股东五洲集团签署的《资产出售协议》及五洲集团在《承诺函》作出的承诺,在交割日前与五洲明珠有关的任何争议、诉讼事项、或有责任相关的所有责任、损失、风险及债务、开支及税费均由五洲
    600873                                         梅花生物科技集团股份有限公司 2013 年第三季度报告集团承担。目前公司正在和五洲集团积极沟通,催告归还上述款项。因此,该等诉讼对公司的生产经营不会产生不利影响。
      3.截止本报告出具日,公司年产 300 吨普鲁兰多糖项目,已有部分产成品产出,由于尚处于工艺摸索阶段,质量稳定性有待提高,仍处于试生产阶段。
    3.3    公司及持股 5%以上的股东承诺事项履行情况√适用 □不适用
                                                                                     是否
                                                                                            是否及
    承诺背    承诺类                                                       承诺时间      有履
                   承诺方                  承诺内容                                         时严格
    景        型                                                           及期限      行期
                                                                                              履行
                                                                                       限
                                                                       36 个月,
                   孟庆山
                            孟庆山及其一致行动人承诺:通过本次交易取   自 2010 年
          股份限   及其一
                            得的股份自登记至其账户之日起三十六个月     12 月 31 日    是      是
            售     致行动
                            内不上市交易或转让。                       至 2014 年
                     人
                                                                       1 月 1 日止
                            在孟庆山先生及一致行动人作为上市公司控
                   孟庆山   股股东或实际控制人之期限内,将采取有效措
          解决同   及其一   施,并促使孟庆山先生或孟庆山先生及一致行
    与重大                                                                                否      是
          业竞争   致行动   动人下属控股子公司采取有效措施,不会从事资产重
                     人     或参与任何可能对上市公司或其控股子公司组相关
                            目前主要从事的业务构成竞争的业务。的承诺
                            在重组完成后,孟庆山先生及一致行动人将尽
                            量避免与上市公司的关联交易,若有不可避免
                   孟庆山   的关联交易,孟庆山先生及一致行动人与上市
          解决关   及其一   公司将依法签订协议,履行合法程序,并将按
                                                                                      否      是
          联交易   致行动   照有关法律、法规、《公司章程》等有关规定
                     人     履行信息披露义务和办理有关报批事宜。保证
                            不通过关联交易损害上市公司及其他股东的
                            合法权益。
                                                                       12 个月,
    与再融             新增六                                              2013 年 3
          股份限            向特定投资者非公开发行的股份自发行结束
    资相关             位机构                                              月 29 日至     是      是
            售              之日起十二个月内不得转让
    的承诺             投资者                                              2014 年 3
                                                                         月 30 日3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明□适用 √不适用
                                                                梅花生物科技集团股份有限公司
                                                                               法定代表人:孟庆山
                                                                          ——————————
                                                                               2013 年 10 月 28 日
    600873                                  梅花生物科技集团股份有限公司 2013 年第三季度报告
    四、   附录4.1
                                   合并资产负债表
                                  2013 年 9 月 30 日编制单位: 梅花生物科技集团股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                      项目                       期末余额                 年初余额流动资产:
    货币资金                                    1,324,632,571.17           863,607,411.88
    结算备付金
    拆出资金
    交易性金融资产                                 80,000,000.00
    应收票据                                      111,587,090.75           353,160,224.69
    应收账款                                      369,382,405.88           296,388,532.90
    预付款项                                      626,124,436.84           819,036,895.74
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                     73,410,741.99            31,008,199.29
    买入返售金融资产
    存货                                        1,455,696,535.77           944,757,172.43
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                              4,040,833,782.40         3,307,958,436.93非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                  148,727,803.29           151,863,027.17
    投资性房地产
    固定资产                                   10,763,457,705.58         5,773,295,917.22
    在建工程                                    2,005,430,302.05         6,514,739,811.73
    工程物资                                       30,819,686.51            99,022,563.68
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                      789,972,909.83           805,775,992.57
    开发支出
    商誉                                           11,788,911.79            11,788,911.79
    长期待摊费用
    递延所得税资产                                  5,659,506.04            10,633,346.68
    其他非流动资产                                672,076,138.51           423,236,819.24
      非流动资产合计                           14,427,932,963.60        13,790,356,390.08
          资产总计                             18,468,766,746.00        17,098,314,827.01流动负债:
    短期借款                                    2,907,818,460.00         2,976,839,312.50
    向中央银行借款
    吸收存款及同业存放
    600873                                       梅花生物科技集团股份有限公司 2013 年第三季度报告
    拆入资金
    交易性金融负债
    应付票据                                           136,860,000.00           165,500,000.00
    应付账款                                         1,472,525,410.27         1,976,865,223.02
    预收款项                                           330,073,996.95           250,134,053.69
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                        27,148,218.12            31,093,084.98
    应交税费                                          -223,970,172.27          -260,020,834.67
    应付利息                                           210,988,648.60           160,468,447.14
    应付股利
    其他应付款                                         457,766,193.02           380,588,966.48
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                             300,000,000.00           600,000,000.00
    其他流动负债                                     1,999,699,333.39         1,995,968,333.89
      流动负债合计                                   7,618,910,088.08         8,277,436,587.03非流动负债:
    长期借款                                         1,000,000,000.00         1,400,000,000.00
    应付债券                                         1,889,521,797.83         1,885,035,664.59
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债                                      62,089,167.56            54,556,053.56
      非流动负债合计                                 2,951,610,965.39         3,339,591,718.15
        负债合计                                    10,570,521,053.47        11,617,028,305.18所有者权益(或股东权益):
    实收资本(或股本)                               3,108,226,603.00         2,708,236,603.00
    资本公积                                         2,240,485,918.58           187,528,409.88
    减:库存股
    专项储备
    盈余公积                                           158,068,747.24           158,068,747.24
    一般风险准备
    未分配利润                                       2,391,464,423.71         2,427,452,761.71
    外币报表折算差额
    归属于母公司所有者权益合计                       7,898,245,692.53         5,481,286,521.83
    少数股东权益
          所有者权益合计                             7,898,245,692.53         5,481,286,521.83
        负债和所有者权益总计                        18,468,766,746.00        17,098,314,827.01
    公司法定代表人: 孟庆山           主管会计工作负责人:李勇刚            会计机构负责人:陶忠
    600873                                   梅花生物科技集团股份有限公司 2013 年第三季度报告
                                  母公司资产负债表
                                  2013 年 9 月 30 日编制单位: 梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                     项目                         期末余额                 年初余额流动资产:
    货币资金                                       524,222,457.58           177,024,125.08
    交易性金融资产
    应收票据                                        36,448,104.00             1,110,000.00
    应收账款                                       366,716,844.53            51,138,661.71
    预付款项                                         4,206,048.10             4,793,310.13
    应收利息
    应收股利                                                                500,000,000.00
    其他应收款                                   6,995,382,148.68         8,530,246,117.81
    存货                                           223,930,348.04            28,405,644.95
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                               8,150,905,950.93         9,292,717,859.68非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                 5,436,727,803.29         2,934,863,027.17
    投资性房地产
    固定资产                                       489,219,903.50           730,588,575.81
    在建工程                                        35,224,423.67            39,164,865.58
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                        96,512,700.98            99,725,962.72
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                                       8,774.68                 8,774.68
    其他非流动资产                                 200,000,000.00
      非流动资产合计                             6,257,693,606.12         3,804,351,205.96
         资产总计                               14,408,599,557.05        13,097,069,065.64流动负债:
    短期借款                                     1,465,000,000.00         1,160,500,000.00
    交易性金融负债
    应付票据                                        10,000,000.00
    应付账款                                       889,041,182.16            59,923,703.56
    预收款项                                       259,954,316.82             1,319,830.93
    应付职工薪酬                                                              5,690,691.50
    应交税费                                       -38,985,503.11            22,659,276.08
    应付利息                                       210,220,996.70           155,180,176.95
    应付股利
    其他应付款                                     722,992,803.24         2,241,065,160.17
    一年内到期的非流动负债                         300,000,000.00           500,000,000.00
    其他流动负债                                 1,999,699,333.39         1,995,968,333.89
    600873                                      梅花生物科技集团股份有限公司 2013 年第三季度报告
      流动负债合计                                  5,817,923,129.20         6,142,307,173.08非流动负债:
    长期借款                                        1,000,000,000.00         1,400,000,000.00
    应付债券                                        1,889,521,797.83         1,885,035,664.59
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                                2,889,521,797.83         3,285,035,664.59
        负债合计                                    8,707,444,927.03         9,427,342,837.67所有者权益(或股东权益):
    实收资本(或股本)                              3,108,226,603.00         2,708,236,603.00
    资本公积                                        2,208,701,622.94           155,744,114.24
    减:库存股
    专项储备
    盈余公积                                          158,068,747.24           158,068,747.24
    一般风险准备
    未分配利润                                        226,157,656.84           647,676,763.49
    所有者权益(或股东权益)合计                        5,701,154,630.02         3,669,726,227.97
        负债和所有者权益(或股东权益)总计         14,408,599,557.05        13,097,069,065.64
    公司法定代表人: 孟庆山           主管会计工作负责人:李勇刚             会计机构负责人:陶忠
    600873                                           梅花生物科技集团股份有限公司 2013 年第三季度报告4.2
                                    合并利润表编制单位: 梅花生物科技集团股份有限公司
                                          单位:元 币种:人民币 审计类型:未经审计
                             本期金额           上期金额       年初至报告期期     上年年初至报告期期
          项目
                           (7-9 月)        (7-9 月)      末金额(1-9 月)     末金额(1-9 月)
    一、营业总收入           1,933,750,459.02   1,613,919,418.05   5,855,259,321.17     5,401,494,334.84
      其中:营业收入     1,933,750,459.02   1,613,919,418.05   5,855,259,321.17     5,401,494,334.84手续费及佣金收入
    二、营业总成本           1,923,507,358.74   1,452,578,983.45   5,636,456,389.94     4,969,136,885.49
      其中:营业成本     1,643,811,805.11   1,238,998,971.68   4,788,806,071.74     4,224,539,777.17
    营业税金及附加             8,551,528.85       5,460,851.63      26,809,068.47        13,485,579.09
            销售费用       139,374,011.67      67,324,115.08     403,655,089.31       237,391,254.45
            管理费用        88,414,807.25      72,820,030.77     275,514,896.59       254,730,918.62
            财务费用        43,355,205.86      67,975,014.29     138,349,571.86       237,147,529.82
    资产减值损失                                                     3,321,691.97         1,841,826.34
      加:公允价值变动收益(损失以“-”号填列)
    投资收益(损失以
    “-”号填列)                 923,171.73      -5,688,156.80       2,302,503.28        -4,525,983.41
    其中:对联营企业和
    合营企业的投资收益            -124,909.25         602,794.70          42,666.59         1,505,409.25
    汇兑收益(损失以“-”号填列)三、营业利润(亏损以
    “-”号填列)              11,166,272.01     155,652,277.80     221,105,434.51       427,831,465.94
      加:营业外收入        55,924,243.31       5,099,945.11     125,645,882.69       100,637,807.48
      减:营业外支出         1,562,229.61       1,200,385.48       2,404,377.85         4,101,278.37
        其中:非流动资
    产处置损失                      19,529.68         174,091.40         233,878.95         2,834,116.19四、利润总额(亏损总
    额以“-”号填列)          65,528,285.71     159,551,837.43     344,346,939.35       524,367,995.05
      减:所得税费用        10,869,946.52      45,075,553.01      69,512,617.05       128,516,968.06五、净利润(净亏损以
    “-”号填列)              54,658,339.19     114,476,284.42     274,834,322.30       395,851,026.99
      归属于母公司所
    有者的净利润                54,658,339.19     114,476,284.42     274,834,322.30       395,851,026.99
      少数股东损益六、每股收益:
      (一)基本每股收
    益                                   0.02               0.04               0.09                 0.15
      (二)稀释每股收
    益                                   0.02               0.04               0.09                 0.15七、其他综合收益
    八、综合收益总额            54,658,339.19     114,476,284.42     274,834,322.30       395,851,026.99
      归属于母公司所
    有者的综合收益总额          54,658,339.19     114,476,284.42     274,834,322.30       395,851,026.99
      归属于少数股东的综合收益总额
    公司法定代表人: 孟庆山             主管会计工作负责人:李勇刚              会计机构负责人:陶忠
    600873                                           梅花生物科技集团股份有限公司 2013 年第三季度报告
                                    母公司利润表编制单位: 梅花生物科技集团股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                                                                                       上年年初至报
                                  本期金额          上期金额        年初至报告期期
           项目                                                                        告期期末金额
                                (7-9 月)       (7-9 月)       末金额(1-9 月)
                                                                                         (1-9 月)
    一、营业收入                 1,135,013,768.80    91,528,908.10     2,089,433,450.60   437,339,313.57
    减:营业成本             1,053,438,364.07   102,910,698.25     1,971,108,319.62   461,767,260.32
          营业税金及附加             41,873.70         597,141.37       1,679,952.71    1,323,951.99
          销售费用               80,574,069.91          62,763.60     141,010,243.19      286,942.53
          管理费用               30,760,132.55    22,544,063.33       107,093,913.09   79,027,504.07
          财务费用                  709,830.98    19,870,283.09          -153,789.97   88,567,462.99
          资产减值损失                                                  6,314,805.07      321,669.31
    加:公允价值变动收益(损失以“-”号填列)
         投资收益(损失以
                                    436,781.16    94,900,888.52           933,055.63   95,812,194.73“-”号填列)
           其中:对联营企
                                   -124,909.25         602,794.70          42,666.59    1,505,409.25业和合营企业的投资收益二、营业利润(亏损以“-”
                                -30,073,721.25    40,444,846.98      -136,686,937.48   -98,143,282.91号填列)
    加:营业外收入              14,280,648.08     1,290,000.00        26,072,203.44    1,657,435.51
    减:营业外支出                     398.15         167,941.69          81,712.31    1,106,539.97
       其中:非流动资产处
                                         99.39          27,679.95           5,738.45      846,948.23置损失三、利润总额(亏损总额以
                                -15,793,471.32    41,566,905.29      -110,696,446.35   -97,592,387.37“-”号填列)
    减:所得税费用                                      9,952.09                       1,700,400.65四、净利润(净亏损以“-”
                                -15,793,471.32    41,556,953.20      -110,696,446.35   -99,292,788.02号填列)五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额               -15,793,471.32    41,556,953.20      -110,696,446.35   -99,292,788.02
    公司法定代表人: 孟庆山            主管会计工作负责人:李勇刚               会计机构负责人:陶忠
    600873                                           梅花生物科技集团股份有限公司 2013 年第三季度报告4.3
                                  合并现金流量表
                                  2013 年 1-9 月编制单位: 梅花生物科技集团股份有限公司
                                          单位:元 币种:人民币 审计类型:未经审计
                                                       年初至报告期期末金额   上年年初至报告期期末
                     项目
                                                             (1-9 月)           金额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                          5,789,655,375.12       5,346,311,887.86
    收到的税费返还                                           51,599,055.99          40,230,361.86
    收到其他与经营活动有关的现金                            222,911,978.44         128,521,376.38
       经营活动现金流入小计                                6,064,166,409.55       5,515,063,626.10
    购买商品、接受劳务支付的现金                          4,157,464,580.90       3,562,598,355.86
    支付给职工以及为职工支付的现金                          332,821,582.44         326,208,067.67
    支付的各项税费                                          379,702,405.28         422,642,603.68
    支付其他与经营活动有关的现金                            480,722,617.82         315,736,455.19
       经营活动现金流出小计                                5,350,711,186.44       4,627,185,482.40
         经营活动产生的现金流量净额                          713,455,223.11         887,878,143.70二、投资活动产生的现金流量:
    收回投资收到的现金                                      135,000,000.00
    取得投资收益收到的现金                                    5,437,727.16             259,558.84
    处置固定资产、无形资产和其他长期资产收回的
                                                               5,355,200.00           2,963,804.53现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
       投资活动现金流入小计                                  145,792,927.16           3,223,363.37
    购建固定资产、无形资产和其他长期资产支付的
                                                           1,179,749,807.41       1,980,689,625.98现金
    投资支付的现金                                          415,000,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
       投资活动现金流出小计                                1,594,749,807.41       1,980,689,625.98
         投资活动产生的现金流量净额                       -1,448,956,880.25      -1,977,466,262.61三、筹资活动产生的现金流量:
    吸收投资收到的现金                                    2,457,778,554.00
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                                    6,391,013,586.13       3,845,936,134.68
    发行债券收到的现金
    收到其他与筹资活动有关的现金
       筹资活动现金流入小计                                8,848,792,140.13       3,845,936,134.68
    偿还债务支付的现金                                    7,006,161,141.02       3,266,225,776.10
    分配股利、利润或偿付利息支付的现金                      615,503,998.08         320,156,371.52
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                            255,597,137.35         188,287,672.67
       筹资活动现金流出小计                                7,877,262,276.45       3,774,669,820.29
         筹资活动产生的现金流量净额                          971,529,863.68          71,266,314.39
    四、汇率变动对现金及现金等价物的影响                         -22,941,716.00           2,804,299.22
    五、现金及现金等价物净增加额                                 213,086,490.54      -1,015,517,505.30
    加:期初现金及现金等价物余额                            580,166,305.18       1,652,684,850.59
    六、期末现金及现金等价物余额                                 793,252,795.72         637,167,345.29
    公司法定代表人: 孟庆山          主管会计工作负责人:李勇刚                 会计机构负责人:陶忠
    600873                                           梅花生物科技集团股份有限公司 2013 年第三季度报告
                                  母公司现金流量表
                                    2013 年 1-9 月编制单位: 梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                                                       年初至报告期期末金额    上年年初至报告期期末金
                     项目
                                                             (1-9 月)              额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                           1,834,674,678.55           472,093,911.88
    收到的税费返还                                                                        203,016.88
    收到其他与经营活动有关的现金                           4,549,161,188.49         4,368,845,022.58
       经营活动现金流入小计                                 6,383,835,867.04         4,841,141,951.34
    购买商品、接受劳务支付的现金                           1,431,452,937.14           422,309,024.78
    支付给职工以及为职工支付的现金                            33,554,403.64            56,166,796.35
    支付的各项税费                                            28,679,069.72            22,896,883.83
    支付其他与经营活动有关的现金                           6,170,618,886.90         4,303,759,801.90
       经营活动现金流出小计                                 7,664,305,297.40         4,805,132,506.86
         经营活动产生的现金流量净额                        -1,280,469,430.36            36,009,444.48二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                   504,068,279.51           400,008,691.66
    处置固定资产、无形资产和其他长期资产收回的
                                                               35,108,200.00            36,044,216.36现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
       投资活动现金流入小计                                   539,176,479.51           436,052,908.02
    购建固定资产、无形资产和其他长期资产支付的
                                                                1,562,371.49            14,081,155.59现金
    投资支付的现金                                         2,710,000,000.00           124,207,837.62
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
       投资活动现金流出小计                                 2,711,562,371.49           138,288,993.21
         投资活动产生的现金流量净额                        -2,172,385,891.98           297,763,914.81三、筹资活动产生的现金流量:
    吸收投资收到的现金                                     2,457,778,554.00
    取得借款收到的现金                                     3,065,000,000.00         2,450,500,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                           4,909,713,444.44         3,112,906,255.25
       筹资活动现金流入小计                                10,432,491,998.44         5,563,406,255.25
    偿还债务支付的现金                                     3,360,500,000.00         1,690,000,000.00
    分配股利、利润或偿付利息支付的现金                       514,780,851.29           206,625,556.48
    支付其他与筹资活动有关的现金                           2,757,093,625.21         4,901,700,000.00
       筹资活动现金流出小计                                 6,632,374,476.50         6,798,325,556.48
         筹资活动产生的现金流量净额                         3,800,117,521.94        -1,234,919,301.23
    四、汇率变动对现金及现金等价物的影响                                   -2.31
    五、现金及现金等价物净增加额                                  347,262,197.29          -901,145,941.94
    加:期初现金及现金等价物余额                             176,130,498.65           953,363,989.00
    六、期末现金及现金等价物余额                                  523,392,695.94            52,218,047.06
    公司法定代表人: 孟庆山           主管会计工作负责人:李勇刚               会计机构负责人:陶忠
数据加载中...
prevnext
手机查看股票